The nonprofit is focused on access to precision medicine testing and treatment for former special operations forces personnel ...

NEW YORK – Fifteen drugs will be offered at a lower cost under Medicare Part D beginning in 2027 after the latest round of drug price negotiations between pharma companies and the Centers for Medicare ...

The FDA recently removed non-ambulatory Duchenne patients from the gene therapy's indication, which Sarepta hopes to have reinstated.

Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...

With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...

The British company's CAR T-cell therapy will now be available through the National Health Service in England and Wales.

From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized ...

The EC considered data from the TRANSCEND NHL 001 trial, in which 83 percent responded to the CAR T-cell therapy and 72 percent had a complete response.

Itvisma has the same active ingredient as Novartis' Zolgensma, but is approved for a broader population of older patients with an intrathecal formulation.

The NSGC is still pushing to achieve Medicare recognition for its members, and said that a counterpart bill will be introduced in the Senate in coming months.

Following guidance from the FDA prioritizing preclinical alternatives to mouse models, some academic and community cancer centers are setting up organoid cores.

The firm plans to explore biomarkers of response for PIN-5018 and its other pipeline candidates to identify best responders to treatment.